+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism



Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism



Hematology/Oncology Clinics of North America 30(5): 1035-1051



In the past 2 decades, the direct oral anticoagulants (DOACs) have emerged as alternatives to the standard therapy (unfractionated or low-molecular-weight heparin followed by vitamin K antagonists [VKA]), for the acute and extended treatment of venous thromboembolism. The DOACs have a more favorable pharmacologic profile and a predictable anticoagulant response and, therefore, have the potential to overcome some of the limitations associated with the use of VKA. Several ongoing registries are evaluating the use of the DOACs in routine clinical practice and will provide additional information in less selected patient populations.

(PDF emailed within 0-6 h: $19.90)

Accession: 059216558

Download citation: RISBibTeXText

PMID: 27637306

DOI: 10.1016/j.hoc.2016.05.008


Related references

Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism. Hamostaseologie 37(4): 241-255, 2017

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism. Blood Research 49(2): 77-79, 2014

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan. Journal of Atherosclerosis and Thrombosis 24(6): 560-565, 2017

Direct oral anticoagulants for venous thromboembolism treatment and prophylaxis. Jaapa 29(8): 24-29, 2018

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Annals of Oncology 2019, 2019

Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics 20(5): 490-500, 2016

Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. F1000research 6: 985, 2017

Direct oral anticoagulants: now also for prevention and treatment of cancer-associated venous thromboembolism?. Hematology. American Society of Hematology. Education Program 2017(1): 136-143, 2018

Optimizing the safety of treatment for venous thromboembolism in the era of direct oral anticoagulants. Polskie Archiwum Medycyny Wewnetrznej 126(9): 688-696, 2016

Direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer. Medicina Clinica 2019, 2019

Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism. Internal and Emergency Medicine 11(7): 895-900, 2017

Evaluation of direct oral anticoagulants for the treatment of venous thromboembolism in the oncology population. Journal of Thrombosis and Thrombolysis 46(4): 483-487, 2018

The use of direct oral anticoagulants in the treatment of acute venous thromboembolism in cancer patients. Expert Review of Hematology 11(6): 487-494, 2018

Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism. Pharmacological Research 118: 33-42, 2016

All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism. Thrombosis and Haemostasis 118(9): 1637-1645, 2018